Latest: FDA Approves New Biosimilar for Oncology Treatment

STAT+: As MAHA turns 1, a fired-up movement is still figuring out how to fulfill its promises

0 Mins
"That is so brilliant. Why didn’t we think of this before?" As MAHA turns 1, STAT examines the growth of the movement and takes stock of its challenges.
Tags:
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago